Drug Trial Radar · NCT07360314
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
138
Planned (sponsor's estimate)
Start
Feb 13, 2026
Primary completion
Sep 28, 2028
Study completion Mar 28, 2029
Sponsor
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Merck KGaA, Darmstadt, Germany
- First posted
- Jan 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this first-in-human (FIH) study is to evaluate the safety, tolerability, Pharmacokinetics (PK), and preliminary clinical activity of M7437 in participants with locally advanced or metastatic solid tumors with known Ly6E expression, including non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), epithelial ovarian carcinoma (EOC), squamous cell carcinoma of the head and neck (SCCHN), pancreatic ductal adenocarcinoma (PDAC), and gastric cancer (GC).
Conditions
- Advanced Solid Tumors
Interventions
M7437Drug
Participants will receive M7437 as an intravenous infusion at a dose corresponding to their assigned cohort. Dose escalation will occur between cohorts, with 3-4 participants enrolled at each dose level before proceeding to the next higher dose.
M7437Drug
Participants will receive M7437 at a dose that was determined as recommended dose for expansion (RDE) in Part 1.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-escalation Cohort: Occurences of Dose Limiting Toxicities (DLTs)Time frame: DLT period is 21 days (cycle 1)
- Dose-escalation Cohort: Number of Participants With Treatment-Emergent Adverse Event (TEAEs) and Adverse Event (AEs)Time frame: Up to end of Part 1 of study (approximately 1 year 8 months)
Locations
9 sites in 4 countries. Site status is shown where the registry gives one.
Yale University - Yale University School of Medicine
New Haven, Connecticut · Recruiting
Carolina BioOncology Institute, LLC - Cancer Therapy and Research Center
Huntersville, North Carolina · Recruiting
NEXT Houston
Galveston, Texas · Recruiting
NEXT Oncology - PARENT
San Antonio, Texas · Recruiting
Princess Margaret Cancer Centre
Toronto, Canada · Recruiting
BC Cancer - Vancouver - BC Cancer Agency
Vancouver, Canada · Not yet recruiting
National Cancer Center Hospital
Tokyo, Japan · Recruiting
Hospital Universitari Vall d'Hebron - VHIO - Oncology - Phase I Unit
Barcelona, Spain · Not yet recruiting
NEXT Madrid - Hospital Universitario Quironsalud Madrid
Madrid, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.